Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN DIEGO -- The ...
Final 5-year follow-up from the BIOFLOW V trial continues to show advantages for the ultrathin-strut bioresorbable-polymer Orsiro DES (Biotronik) over the thin-strut, durable-polymer Xience (Abbott), ...
BÜLACH, Switzerland--(BUSINESS WIRE)--BIOTRONIK announced today the start of an international study comparing the company’s ORSIRO sirolimus-eluting coronary stent with Abbott Laboratory’s XIENCE ...
BARCELONA, Spain—Among all the big trials airing results at the European Society of Cardiology (ESC) Congress 2017, one tiny stent—and its performance—could have slipped through the cracks. Earlier ...
SAN DIEGO and BUELACH, Switzerland, Sept. 24, 2018 /PRNewswire/ -- Today, BIOTRONIK announced two-year data from the BIOFLOW-V randomized trial comparing the Orsiro a and Xience b drug-eluting stents ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback